



Total syntheses of (±)-folicanthine and (±)-chimonanthine via a double intramolecular carbamoylketene–alkene [2+2] cycloaddition

Takaaki Araki, Yuki Manabe, Kosuke Fujioka, Hiromasa Yokoe, Makoto Kanematsu, Masahiro Yoshida, Kozo Shishido*

Graduate School of Pharmaceutical Sciences, The University of Tokushima, 1-78-1 Sho-machi, Tokushima 770-8505, Japan

ARTICLE INFO

Article history:

Received 3 November 2012

Revised 5 December 2012

Accepted 14 December 2012

Available online 22 December 2012

Keywords:

Total synthesis

Alkaloid

Cycloaddition

Indole

Nitrone

ABSTRACT

Total syntheses of the dimeric pyrrolidinoindoline alkaloids folicanthine and chimonanthine have been accomplished in racemic forms employing a double intramolecular carbamoylketene–alkene [2+2] cycloaddition as the key step.

© 2012 Elsevier Ltd. All rights reserved.

Folicanthine (**1**)¹ and chimonanthine (**2**)² are representatives of the dimeric pyrrolidinoindoline alkaloids³ that have been isolated from the leaves of *Calycanthus floridus* L. and from the deciduous shrub *Chimonanthus fragrans*, respectively. Because of their fascinating structural array and biological profile,⁴ these alkaloids are considered attractive targets for total synthesis. To date, a number of syntheses of the racemic⁵ and optically active forms⁶ have been reported. Interestingly, it was found that chimonanthine (**2**) could be converted into the isomeric alkaloid calycanthine (**3**) and folicanthine (**1**) by acidic treatment and reductive N-methylation, respectively^{6c,d} (Fig. 1).

Previously, we developed an efficient intramolecular carbamoylketene–alkene [2+2] cycloaddition reaction (**4** → **5**) and demonstrated that the methodology could be successfully applied to the syntheses of the physovenine intermediate **6**,^{7a} esermethole (**7**),^{7b} and debromoflustramines B (**8**) and E (**9**).^{7c} In an attempt to probe the further applicability of the cycloaddition, we chose both alkaloids **1** and **2** as the synthetic targets. Here we describe the total syntheses of (±)-folicanthine (**1**) and (±)-chimonanthine (**2**), employing a novel type of double intramolecular carbamoylketene–alkene [2+2] cycloaddition as the key step (Scheme 1).

Our retrosynthetic analysis is shown in Scheme 2. We thought that folicanthine (**1**) and chimonanthine (**2**) might be derived from **10** via a regio-selective ring expansion followed by appropriate functional group transformations. The bis-cyclobutanone **10** could

be assembled by a double intramolecular [2+2] cycloaddition of the dienyl ketene **11**, which could be derived from 2,3-diaryl-1,3-butadiene **12**. The symmetrical diene can be prepared by palladium-catalyzed coupling of 2-nitrophenylboronic acid (**13**)⁸ with the carbonate of butynediol **14**⁹ (Scheme 2).

Based on the procedure reported by Grigg,^{10a} we examined the preparation of the starting 2,2'-(buta-1,3-diene-2,3-diyl)bis(nitrobenzene) (**12**) shown in Table 1. Treatment of a mixture of **13** and **14** with a 10 mol % of Pd(PPh₃)₄ in THF at 70 °C provided the requisite diene **12** in 52% yield (entry 1). The reaction at the higher temperature of 100 °C in dioxane resulted in a slightly improved yield of 58% (entry 2). When the reaction was conducted with Pd₂(dba)₃·CHCl₃ (10 mol %) in the presence of a ligand (40 mol %) in THF at 70 °C, the yields increased gradually depending upon the ligand (entries 3–5). The best result was obtained with dppe, which provided **12** in 68% yield (entry 5).






Figure 1. Dimeric pyrrolidinoindoline alkaloids.

* Corresponding author. Tel.: +81 88 6337287; fax: +81 88 6339575.

E-mail address: shishido@ph.tokushima-u.ac.jp (K. Shishido).



Scheme 1. Syntheses of pyrrolidinoindoline alkaloids.




Scheme 2. Retrosynthetic analysis.

Table 1
Pd-catalyzed preparation of diarylated diene **12**

		13 + 14 (1 equiv.) (1 equiv.)		conditions		12	
Entry	Pd species (10 mol %)	Ligand (40 mol %)	Solvent	Temp (°C)	Yield (%)		
1	Pd(PPh ₃) ₄	—	THF	70	52		
2	Pd(PPh ₃) ₄	—	1,4-Dioxane	100	58		
3	Pd ₂ (dba) ₃ ·CHCl ₃	dppb	THF	70	53		
4	Pd ₂ (dba) ₃ ·CHCl ₃	dppm	THF	70	61		
5	Pd ₂ (dba) ₃ ·CHCl ₃	dppe	THF	70	68		

With the symmetrical diene **12** in hand, we then turned our attention to the key double [2+2] cycloaddition. Initially, diene **12** was converted into bis-carboxylic acid **18**, which is a precursor of ketene **11**, by sequential reduction of the nitro group, carbomethoxylation, alkylation with methyl bromoacetate, and alkaline hydrolysis in 63% yield for the four steps. Treatment of **18** with




Scheme 3. Synthesis of (±)-folicanthine (**1**). Reagents and conditions: (a) Zn, AcOH, rt, 1 h, 73%; (b) ClCO₂Me, K₂CO₃, THF, H₂O, rt, 10 min, 86%; (c) BrCH₂CO₂Me, NaH, DMF, rt, 1.5 h, quant.; (d) LiOH·H₂O, THF, H₂O, rt, 1 h, quant.; (e) (COCl)₂, benzene, rt, 1 h then 85 °C, 30 min; (f) Et₃N, benzene, 90 °C, 1 h, 89% (2 steps); (g) MeNH₂·HCl, NaHCO₃, MS 3A, EtOH, 50 °C, 4 h then *p*-TsCl, 4-DMAP, CHCl₃, 70 °C, 3 h, 62% (2 steps); (h) LiAlH₄, THF, reflux, 1.5 h, 36% for **1**, 28% for *meso*-**1**.

oxalyl chloride in benzene provided the acid chloride, to which triethylamine was added in one pot at 90 °C to give an inseparable mixture of (±)-**10** and the *meso*-**10**¹¹ in 89% yield. The mixture was then treated with *N*-methylhydroxylamine hydrochloride, NaHCO₃, and 3A molecular sieves in ethanol at 50 °C to afford the corresponding nitrone,¹² which, without purification, was immediately reacted with *p*-TsCl and 4-dimethylaminopyridine (4-DMAP) in refluxing chloroform to furnish the bis-lactam **19**¹³ in 62% yield as an inseparable mixture. Thus, we were able to install the bis-hexahydropyrrolo[2,3-*b*]indole backbone by a double carbamoylketene–alkene [2+2] cycloaddition. Reduction of **19** with lithium aluminum hydride (LiAlH₄) in refluxing THF for 1.5 h provided a mixture of (±)-folicanthine (**1**)¹⁴ and *meso*-folicanthine (*meso*-**1**),¹⁵ which was separated by preparative TLC, in 36% and 28% yields, respectively. The spectroscopic properties of the synthetic **1** and *meso*-**1** were identical with those reported in the literature^{5f,16} (Scheme 3).

For the synthesis of chimonanthine (**2**), **19** was hydrolyzed under alkaline conditions to give a 1.7:1 mixture (from ¹H NMR) of (±)-**20**¹⁷ and the *meso*-**20**¹⁸ in 79% yield.¹⁹ When placed in chloroform, the (±)-**20** dissolved smoothly whereas the *meso*-**20** remained an insoluble solid. Thus, we were able to separate the mixture without using chromatography. The (±)-**20** was exposed to LiAlH₄ in refluxing THF for 0.5 h to give (±)-chimonanthine (**2**)²⁰ in 73% yield, the spectral properties of which were identical with those reported in the literature.^{6d} It should be noted that attempted reduction of the *meso*-**20** with LiAlH₄ did not give *meso*-chimonanthine at all, but instead a mixture of unidentified products (Scheme 4).

In summary, the total syntheses of (±)-folicanthine (**1**) and (±)-chimonanthine (**2**) have been accomplished employing a novel and efficient double intramolecular carbamoylketene–alkene [2+2] cycloaddition as the key step, thus opening a fascinating entry to the dimeric pyrrolidino[2,3-*b*]indolines. The synthetic method developed here is general and efficient and could also be applied



Scheme 4. Synthesis of (±)-chimonanthine.

to the synthesis of other related dimeric alkaloids with more complicated molecular structures.

Acknowledgments

We are grateful to Professor Hiromitsu Takayama, Chiba University, for providing a sample of the natural folicanthine and spectral data (¹H and ¹³C NMR) of *meso*-folicanthine. This work was supported financially by a Grant-in-Aid for the Program for Promotion of Basic and Applied Research for Innovations in the Bio-oriented Industry (BRAIN) and a Grant-in-Aid for Scientific Research (B) (23390026) from the JSPS.

References and notes

- Eiter, K.; Svierak, O. *Monatshefte* **1951**, *82*, 186–188.
- Hodson, H. F.; Robinson, B.; Smith, G. F. *Proc. Chem. Soc.* **1961**, 465–466.
- For reviews, see: (a) Steven, A.; Overman, L. E. *Angew. Chem., Int. Ed.* **2007**, *46*, 5488–5508; (b) Schmidt, M. A.; Movassaghi, M. *Synlett* **2008**, 313–324.
- (a) Amador, T. A.; Verotta, L.; Nunes, D. S.; Elisabetsky, E. *Planta Med.* **2000**, *66*, 770–772; (b) Verotta, L.; Orsini, F.; Sbaccio, M.; Scheidler, M. A.; Elisabetsky, E. *Bioorg. Med. Chem.* **2002**, *10*, 2133–2142; (c) Zhang, J.-W.; Gao, J.-M.; Xu, T.; Zhang, X.-C.; Ma, Y.-T.; Jarussophon, S.; Konishi, Y. *Chem. Biodivers.* **2009**, *6*, 838–845.
- For the racemic syntheses of chimonanthine and folicanthine, see: (a) Hino, T.; Yamada, S. *Tetrahedron Lett.* **1963**, *4*, 1757–1760; (b) Scott, A. I.; Guo, L.; McCapra, F.; Hall, E. S. *J. Am. Chem. Soc.* **1964**, *86*, 302–303; (c) Hendrickson, J. B.; Goschke, R.; Ress, R. *Tetrahedron* **1964**, *20*, 565–579; (d) Hall, E. S.; McCapra, F.; Scott, A. I. *Tetrahedron* **1967**, *23*, 4131–4141; (e) Hino, T.; Kodato, S.; Takahashi, K.; Yamaguchi, H.; Nakagawa, M. *Tetrahedron Lett.* **1978**, *19*, 4913–4916; (f) Fang, C.-L.; Horne, S.; Taylor, R.; Rodrigo, R. *J. Am. Chem. Soc.* **1994**, *116*, 9480–9486; (g) Ishikawa, H.; Takayama, H.; Aimi, N. *Tetrahedron Lett.* **2002**, *43*, 5637–5639; (h) Matsuda, Y.; Kitajima, M.; Takayama, H. *Heterocycles* **2005**, *65*, 1031–1033; (i) Li, Y.-X.; Wang, H.-X.; Ali, S.; Xia, X.-F.; Liang, Y.-M. *Chem. Commun.* **2012**, 2343–2345.
- For the asymmetric syntheses of chimonanthine and folicanthine, see: (a) Overman, L. E.; Paone, D. V.; Stearns, B. A. *J. Am. Chem. Soc.* **1999**, *121*, 7702–7703; (b) Overman, L. E.; Larrow, J. F.; Stearns, B. A.; Vance, J. M. *Angew. Chem., Int. Ed.* **2000**, *39*, 213–215; (c) Movassaghi, M.; Schmidt, M. A. *Angew. Chem., Int. Ed.* **2007**, *46*, 3725–3728; (d) Mitsunuma, H.; Shibasaki, M.; Kanai, M.; Matsunaga, S. *Angew. Chem., Int. Ed.* **2012**, *51*, 5217–5221; (e) Guo, C.; Song, J.; Huang, J. Z.; Chen, P. H.; Luo, S. W.; Gong, L. Z. *Angew. Chem., Int. Ed.* **2012**, *51*, 1046–1050.
- (a) Shishido, K.; Azuma, T.; Shibuya, M. *Tetrahedron Lett.* **1990**, *31*, 219–220; (b) Ozawa, T.; Kanematsu, M.; Yokoe, H.; Yoshida, M.; Shishido, K. *Heterocycles* **2012**, *85*, 2927–2932; (c) Ozawa, T.; Kanematsu, M.; Yokoe, H.; Yoshida, M.; Shishido, K. *J. Org. Chem.* **2012**, *77*, 9240–9249.
- Collibee, S. E.; Yu, J. *Tetrahedron Lett.* **2005**, *46*, 4453–4455.
- Kiji, J.; Okano, T.; Fujii, E.; Tsuji, J. *Synthesis* **1997**, 869–870.
- (a) Bohmer, J.; Grigg, R. *Tetrahedron* **1999**, *55*, 13463–13470; (b) Nishioka, N.; Hayashi, S.; Koizumi, T. *Angew. Chem., Int. Ed.* **2012**, *51*, 3682–3685.
- Compound **10** (1:1 mixture of (±)-**10** and *meso*-**10**): IR (neat) 2955, 1794, 1714 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 3.38 (2H, dd, *J* = 2.8, 12.0 Hz), 3.40 (2H, dd, *J* = 2.8, 17.6 Hz), 3.77–3.92 (16H, m), 5.20–5.75 (4H, m), 6.73 (2H, d, *J* = 7.6 Hz), 6.90–6.99 (2H, m), 6.97 (2H, t, *J* = 7.6 Hz), 7.13 (2H, d, *J* = 7.6 Hz), 7.15–7.26 (2H, m), 7.33 (2H, t, *J* = 7.6 Hz), 7.70–7.95 (4H, m); ¹³C NMR (CDCl₃, 100 MHz) δ 47.5 (C × 4), 53.1 (CH₃ × 2), 53.3 (CH₃ × 2), 57.3 (CH₂ × 2), 57.5 (CH₂ × 2), 78.2 (CH × 2), 78.9 (CH × 2), 116.2 (CH × 4), 123.8 (CH × 2), 124.2 (CH × 4), 124.6 (CH × 2), 129.7 (CH × 2), 130.1 (CH × 2), 130.9 (C × 4), 143.8 (C × 4), 152.3 (C × 4), 200.9 (C × 2), 201.1 (C × 2); HRMS (ESI-TOF) *m/z* calcd for C₂₄H₂₁N₂O₆ [M+H]⁺: 433.1400, found 433.1394.
- (a) Barton, D. H. R.; Day, M. J.; Hesse, R. H.; Pechet, M. M. *J. Chem. Soc., Chem. Commun.* **1971**, 945–946; (b) Jeffs, P. W.; Molina, G.; Cortesst, N. A.; Hauck, P. R.; Wolfram, J. *J. Org. Chem.* **1982**, *47*, 3876–3881; (c) Hoffman, R. V.; Salvador, J. M. *Tetrahedron Lett.* **1989**, *30*, 4207–4210.
- Compound **19** (1:1 mixture of (±)-**19** and *meso*-**19**): IR (neat) 2956, 1704, 1485 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 2.66–3.08 (20H, m), 3.62–3.95 (12H, m), 5.15–5.95 (4H, m), 6.98–7.81 (16H, m); ¹³C NMR (CDCl₃, 100 MHz) δ 27.2 (CH₃ × 2), 27.3 (CH₃ × 2), 38.0 (CH₂ × 4), 39.2 (C × 4), 53.3 (CH₃ × 4), 79.9 (CH × 2), 80.5 (CH × 2), 117.3 (CH × 2), 117.6 (CH × 2), 124.1 (CH × 2), 124.3 (CH × 2), 124.8 (CH × 4), 130.0 (CH × 2), 130.2 (CH × 2), 131.8 (C × 4), 139.6 (C × 2), 140.5 (C × 2), 152.1 (C × 2), 154.2 (C × 2), 170.2 (C × 2), 170.5 (C × 2); HRMS (ESI-TOF) *m/z* calcd for C₂₆H₂₇N₄O₆ [M+H]⁺: 491.1931, found 491.1908.
- Compound (±)-**1**: Mp 166–167 °C (hexane/AcOEt); IR (KBr) 1602, 1490, 1347, 1157, 735 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 1.92–1.98 (2H, m), 2.30–2.49 (4H, m), 2.41 (6H, s), 2.58–2.67 (2H, m), 3.00 (6H, s), 4.40 (2H, br), 6.46 (2H, d, *J* = 7.6 Hz), 6.47–6.51 (2H, m), 6.88–6.93 (2H, m), 6.97 (2H, t, *J* = 7.2 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 35.2 (CH₂ × 2), 35.4 (CH₃ × 2), 37.7 (CH₃ × 2), 52.5 (CH₂ × 2), 62.5 (CH × 2), 91.8 (C × 2), 105.7 (CH × 2), 116.5 (CH × 2), 123.6 (CH × 2), 128.0 (CH × 2), 132.6 (C × 2), 152.8 (C × 2); HRMS (ESI-TOF) *m/z* calcd for C₂₄H₃₀N₄Na [M+Na]⁺: 397.2368, found 397.2361.
- meso*-**1**: Mp 161–162 °C (hexane/AcOEt); IR (KBr) 2926, 1601, 1494, 743 cm⁻¹; ¹H NMR (C₅D₅N, 400 MHz) δ 1.68 (2H, dd, *J* = 4.6, 11.4 Hz), 2.09 (6H, s), 2.18–2.46 (12H, m), 4.17 (2H, br), 6.17 (2H, d, *J* = 7.6 Hz), 6.20–6.40 (2H, m), 6.50–7.05 (4H, m); ¹³C NMR (C₅D₅N, 100 MHz, 90 °C) δ 37.0 (CH₂ × 2), 37.4 (CH₃ × 2), 37.7 (CH₃ × 2), 53.5 (CH₂ × 2), 64.6 (CH × 2), 91.9 (C × 2), 108.4 (CH × 2), 118.5 (CH × 2), 125.3 (CH × 2), 129.5 (CH × 2), 135.7 (C × 2), 155.2 (C × 2); HRMS (ESI-TOF) *m/z* calcd for C₂₄H₃₁N₄ [M+H]⁺: 375.2549, found 375.2533.
- Takayama, H.; Matsuda, Y.; Masubuchi, K.; Ishida, A.; Kitajima, M.; Aimi, N. *Tetrahedron* **2004**, *60*, 893–900.
- Compound (±)-**20**: IR (neat) 3403, 1662, 1484 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 2.66 (6H, s), 2.78 (2H, d, *J* = 16.8 Hz), 3.11 (2H, d, *J* = 16.8 Hz), 4.70 (2H, s), 6.68 (2H, d, *J* = 7.6 Hz), 6.84 (2H, t, *J* = 7.6 Hz), 7.15 (2H, t, *J* = 7.6 Hz), 7.23 (2H, d, *J* = 7.6 Hz), 2H of –NH– were not observed clearly; ¹³C NMR (CDCl₃, 100 MHz) δ 26.4 (CH₂ × 2), 39.3 (CH₂ × 2), 55.3 (C × 2), 80.4 (CH × 2), 111.1 (CH × 2), 120.6 (CH × 2), 125.1 (CH × 2), 129.8 (CH × 2), 130.8 (C × 2), 148.2 (C × 2), 171.4 (C × 2); HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₃N₄O₂ [M+H]⁺: 375.1821, found 375.1830.
- meso*-**20**: Mp 360 °C (decomp.) (MeOH/CHCl₃); IR (KBr) 3403, 1661, 1482 cm⁻¹; ¹H NMR (C₅D₅N, 400 MHz) δ 2.87 (6H, s), 3.10 (2H, d, *J* = 16.8 Hz), 3.37 (2H, d, *J* = 16.8 Hz), 5.52 (2H, d, *J* = 2.4 Hz), 6.68 (2H, d, *J* = 8.0 Hz), 6.72 (2H, br), 6.81 (2H, br), 7.14 (4H, t, *J* = 8.0 Hz); ¹³C NMR (C₅D₅N, 100 MHz) δ 26.6 (CH₂ × 2), 41.5 (CH₂ × 2), 56.3 (C × 2), 79.9 (CH × 2), 110.7 (CH × 2), 119.3 (CH × 2), 125.1 (CH × 2), 129.8 (CH × 2), 132.0 (C × 2), 150.6 (C × 2), 171.4 (C × 2); HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₃N₄O₂ [M+H]⁺: 375.1821, found 375.1829.
- Treatment of a mixture (1.7:1) of **20** with LiAlH₄ in refluxing THF for 3 h provided (±)-**2** and the recovered *meso*-**20** in 29% and 6% yield, respectively.
- Compound (±)-**2**: Mp 168–172 °C (benzene); IR (KBr) 3297, 2932, 1605, 1486 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz, 50 °C) δ 2.03–2.08 (2H, m), 2.31 (6H, s), 2.49–2.58 (6H, m), 4.44 (2H, br), 6.53 (2H, d, *J* = 7.5 Hz), 6.66 (2H, t, *J* = 7.5 Hz), 6.98 (2H, t, *J* = 7.5 Hz), 7.18 (2H, d, *J* = 7.5 Hz), 2H of –NH– were not observed clearly; ¹³C NMR (CDCl₃, 125 MHz, 50 °C) δ 35.5 (CH₂ × 2), 37.0 (CH₃ × 2), 52.7 (CH₂ × 2), 63.3 (C × 2), 85.3 (CH × 2), 109.3 (CH × 2), 118.7 (CH × 2), 124.4 (CH × 2), 128.2 (CH × 2), 133.0 (C × 2), 150.7 (C × 2); HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₆N₄Na [M+Na]⁺: 369.2055, found 369.2054.